1.55
-0.04(-2.52%)
Currency In USD
| Previous Close | 1.59 |
| Open | 1.61 |
| Day High | 1.67 |
| Day Low | 1.55 |
| 52-Week High | 12.3 |
| 52-Week Low | 1.31 |
| Volume | 36,855 |
| Average Volume | 125,420 |
| Market Cap | 31.25M |
| PE | -0.6 |
| EPS | -2.57 |
| Moving Average 50 Days | 1.55 |
| Moving Average 200 Days | 3.8 |
| Change | -0.04 |
If you invested $1000 in CalAmp Corp. (CAMP) 10 years ago, it would be worth $4.42 as of August 24, 2025 at a share price of $1.55. Whereas If you bought $1000 worth of CalAmp Corp. (CAMP) shares 5 years ago, it would be worth $7.67 as of August 24, 2025 at a share price of $1.55.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting
GlobeNewswire Inc.
May 16, 2025 10:00 AM GMT
Haploinsufficient SYNGAP1 mice treated with CMP-SYNGAP-01 demonstrated an increase in SYNGAP1 protein levels; treatment rescued multiple SYNGAP1-dependent behavioral phenotypes CMP-SYNGAP-01 administration led to a significant increase in SYNGAP1 pro
CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting
GlobeNewswire Inc.
Apr 28, 2025 8:30 PM GMT
Preclinical data to showcase the potential of regRNA-targeting to increase protein levels in a clinically meaningful way by upregulating gene expression Interim safety data including patient demographic data from all SAD cohorts of the first-in-human
CAMP4 Appoints Multiple Industry Veterans to its Board of Directors
GlobeNewswire Inc.
Mar 18, 2025 12:00 PM GMT
With decades of experience in pharmaceutical development and extensive genetic medicine expertise, Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP, will provide strategic guidance for CAMP4’s multiple drug development efforts CAMBRIDGE, Mass., M